DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport. Healthcare issues related to clinical laboratories;

H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;

Federal policy related to implementation of the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured;

Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;

Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;

H.R. 7179, The Pandemic Liability Protection Act, H.R. 7059, the Coronavirus Provider Protection Act, and H.R. 7528, the Get America Back to Work Act, provisions relating to limitation of liability for COVID-19 related services;

H.R. 7615/S.4214, the Healthy Workplace Tax Credit Act, and H.R. 7658, the Workplace Testing Tax Credit Act, provisions relating to employer tax credits for back-to-work COVID-19 testing;

The Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act (Draft bill), and Section 109 of S. 4322, the Safely Back to School and Back to Work Act, provisions relating to requiring informed consent for secondary uses of human genetic information obtained through COVID-19 testing;

Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;

H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time; 

Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation;

Federal policy relating to drug development, including potential legislation known as Cures 2.0;

Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and

Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
TRA - Transportation HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 South Spring Street, Burlington, NC, 27215, US
DONALD HORTON KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL